Beam Therapeutics Inc. Deferred Tax Assets, Operating Loss Carryforwards
Beam Therapeutics Inc. (BEAM) had Deferred Tax Assets, Operating Loss Carryforwards of $141.13 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $141.13M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $48.95M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $3.96M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $25.74M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $141.13M 10-K · filed 2026-02-24 |
| 2024-12-31 | $48.95M 10-K · filed 2026-02-24 |
| 2023-12-31 | $3.96M 10-K · filed 2025-02-25 |
| 2022-12-31 | $25.74M 10-K · filed 2024-02-27 |
| 2021-12-31 | $103.87M 10-K · filed 2023-02-28 |
| 2020-12-31 | $58.34M 10-K · filed 2022-02-28 |
| 2019-12-31 | $26.77M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |